7135 East Camelback Road
Scottsdale, AZ 85251

Velawcity © 2018

TAXOTERE LAWSUITS

WHAT IS TAXOTERE?

Taxotere was released in the United States in 1996 and is the most prescribed chemotherapy drug to treat breast cancer. It is manufactured by Sanofi-Aventis and was originally approved by the FDA in 1996. Approximately 3 million women in the United States are living with breast cancer and oncologists use Taxotere to treat about 75 percent of these cases.

Taxotere stops cells from dividing and multiplying. Healthy cells normally stop dividing when they are around other healthy cells. On the contrary, cancer cells do not have the ability to stop dividing which is how cancer continues to spread. Taxotere is used to attack cancer cells and stop growth.

GEICAM 9805 Trial Study (2005)

The New England Journal of Medicine published the study on December 2nd, 2010. The data revealed that 9.2% of cancer patients given Taxotere reported permanent hair loss. The GEICAM 9805 study evaluated 1,060 patients.   

FOOD & DRUG ADMINISTRATION (FDA)

December, 2015

Food and Drug Administration (FDA) orders manufacturer Sanofi-Aventis to update chemotherapy drug Taxotere's warning label to include risks for permanent hair loss or alopecia. The label update was approved on December 11th, 2015.

June 20th, 2014

The FDA releases a Drug Safety Communication warning that chemotherapy drug docetaxel contains ethanol, which may cause patients to experience intoxication or drunk like symptoms. 

April 16th, 2009

FDA sends a letter to Sanofi-Aventis warning the company their claim that Taxotere works better than competitor Taxol was false and was considered Misbranding, a federal crime. 

COMPLICATIONS

CLINICAL TRIALS

The most significant complication women are experiencing is permanent Alopecia, otherwise referred to as permanent baldness. Chemotherapy is synonymous with hair loss, though most cases resolve themselves within 3-6 months after completion of treatment. Alopecia is irreversible and can happen anywhere on a woman's body.

TAXOTERE LAWSUIT UPDATES

Overview

MDL 2740:  October 4th, 2016

Judge:  Kurt D. Engelhardt

Venue:  Eastern District of Louisiana

Pending Actions:  1,272

 

Bellwether Trials

  • September 24th, 2018

  • January 28th, 2019

  • April 8th, 2019

  • July 15th, 2019

  • November 4th, 2019

Sources: (1) (2) (3)

 
 
 

FROM THE BLOG

JPML Approves Onglyza Consolidation

February 7, 2018

Essure Ban Lifted by Brazil

August 10, 2017

IVC Filter Implants Decrease Nationwide

August 8, 2017

PPI Approved for Centralization by JPML

August 3, 2017

1/1
Please reload